• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Continuing Colorectal Cancer Screening After Age 75 Lead to Fewer Cases of Cancer and Related Deaths?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • USPSTF recommends continuing colorectal cancer (CRC) screening through age 75, followed by individual decisions on screening for those over 75 | Data is limited for this age group
  • Ma et al. (JAMA Oncology, 2021) examined the association of lower gastrointestinal tract screening endoscopy with the risk of CRC incidence and CRC-related mortality in older US adults

METHODS:

  • Prospective cohort study
  • Population
    • Health care professionals in the US
      • Nurses’ Health Study (NHS): Jan 1988 to Jun 2016
      • Health Professionals Follow-up Study (HPFS): Jan 1988 to Jan 2016
  • Exposures
    • History of screening sigmoidoscopy or colonoscopy (routine/average risk or positive family history), assessed every 2 years
      • To 75 years of age
      • After 75 years of age
  • Primary outcomes
    • CRC incidence
    • CRC-related mortality: Confirmed by National Death Index, medical records, and pathology reports

RESULTS:

  • 56,374 participants reached 75 years of age during follow-up
    • 63.2% women
    • Incident CRC cases: 661
    • CRC-related deaths: 323
  • Regardless of screening history, screening endoscopy after 75 years of age was associated with reduced risk of
    • CRC incidence (primarily distal colon and rectal)
      • Hazard ratio 0.61 (95% CI, 0.51 to 0.74)
    • CRC-related mortality
      • HR 0.60 (95% CI, 0.46 to 0.78)
  • Broken down by screening history, there was still a reduced risk of CRC incidence and related mortality with screening after age 75
    • Screening endoscopy <75
      • CRC incidence: 0.67 (95% CI, 0.50 to 0.89)
      • CRC-related mortality: 0.58 (95% CI 0.38 to 0.87)
    • No screening history
      • CRC incidence: 0.51 (95% CI, 0.37 to 0.70)
      • CRC-related mortality: 0.63 (95% CI, 0.43 to 0.93)
  • Screening endoscopy >75 years of age was not associated with risk reduction in CRC death among participants with
    • Cardiovascular disease: HR 1.18 (95% CI, 0.59 to 2.35)
    • Significant comorbidities: HR 1.17 (95% CI, 0.57 to 2.43)

CONCLUSION:

  • Endoscopy screening for those older than 75 was associated with a reduced risk of CRC and CRC-related mortality, regardless of prior screening history
    • However, there was no risk reduction with screening after 75 if the individual had cardiovascular disease or significant comorbidities
  • The results of this study support continued screening after 75 years of age for individuals without significant comorbidities
  • The authors state

Given the difficulty of conducting randomized clinical trials of screening among older adults with sufficient follow-up, our data provide an important contribution in addressing this question

Our findings provide evidence for patients, physicians, and policy makers to make informed decisions about CRC screening in an older population

Learn More – Primary Sources:

Association of Screening Lower Endoscopy With Colorectal Cancer Incidence and Mortality in Adults Older Than 75 Years

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Professional Guidelines: Colorectal Cancer Screening
What Percentage of Individuals under 50 Years of Age with Colon Cancer Have Mutations Associated with Heritable Cancer?
Is Obesity Associated with Higher Risk of Early-Onset Colorectal Cancer in Women?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site